Palisade Bio Says Ulcerative Colitis Patients Respond to PALI-2108 Treatment in Phase 1b Trial

MT Newswires Live

Sep 17, 2025

Palisade Bio (PALI) said Wednesday that a phase 1b trial of its investigational drug PALI-2108 in ulcerative colitis showed 100% clinical response, with all five patients responding to treatment.

The study also showed "promising" efficacy data, with two of the five patients achieving clinical remission after seven days based on US Food and Drug Administration-defined endpoints, the company said.

PALI-2108 also showed a "favorable" safety profile and support anti-fibrotic activity, expanding development potential into fibrostenotic Crohn's disease, Palisade said.

The company said it expects to begin patient dosing in a phase 1b trial in fibrostenotic Crohn's disease within the year and targets to file in H1 of 2026 an investigational new drug application for a phase 2 trial.

Palisade shares were up more than 4% in recent trading Wednesday.

Price: 0.63, Change: +0.03, Percent Change: +4.58

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2568494530"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568494530\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568494530?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-17 21:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568494530","market":"sg","top_or_hot":-1,"title":"Palisade Bio Says Ulcerative Colitis Patients Respond to PALI-2108 Treatment in Phase 1b Trial","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PALI\">Palisade Bio</a> (PALI) said Wednesday that a phase 1b trial of its investigational drug PALI-2108 in ulcerative colitis showed 100% clinical response, with all five patients responding to treatment.</p><p>The study also showed \"promising\" efficacy data, with two of the five patients achieving clinical remission after seven days based on US Food and Drug Administration-defined endpoints, the company said.</p><p>PALI-2108 also showed a \"favorable\" safety profile and support anti-fibrotic activity, expanding development potential into fibrostenotic Crohn's disease, Palisade said.</p><p>The company said it expects to begin patient dosing in a phase 1b trial in fibrostenotic Crohn's disease within the year and targets to file in H1 of 2026 an investigational new drug application for a phase 2 trial.</p><p>Palisade shares were up more than 4% in recent trading Wednesday.</p><p>Price: 0.63, Change: +0.03, Percent Change: +4.58</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palisade Bio Says Ulcerative Colitis Patients Respond to PALI-2108 Treatment in Phase 1b Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalisade Bio Says Ulcerative Colitis Patients Respond to PALI-2108 Treatment in Phase 1b Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-17 21:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PALI\">Palisade Bio</a> (PALI) said Wednesday that a phase 1b trial of its investigational drug PALI-2108 in ulcerative colitis showed 100% clinical response, with all five patients responding to treatment.</p><p>The study also showed \"promising\" efficacy data, with two of the five patients achieving clinical remission after seven days based on US Food and Drug Administration-defined endpoints, the company said.</p><p>PALI-2108 also showed a \"favorable\" safety profile and support anti-fibrotic activity, expanding development potential into fibrostenotic Crohn's disease, Palisade said.</p><p>The company said it expects to begin patient dosing in a phase 1b trial in fibrostenotic Crohn's disease within the year and targets to file in H1 of 2026 an investigational new drug application for a phase 2 trial.</p><p>Palisade shares were up more than 4% in recent trading Wednesday.</p><p>Price: 0.63, Change: +0.03, Percent Change: +4.58</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PALI","symbol_name":"Palisade Bio Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568494530","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568494530","pubTimestamp":1758117195,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Palisade Bio  said Wednesday that a phase 1b trial of its investigational drug PALI-2108 in ulcerative colitis showed 100% clinical response, with all five patients responding to treatment.The study also showed \"promising\" efficacy data, with two of the five patients achieving clinical remission after seven days based on US Food and Drug Administration-defined endpoints, the company said.PALI-2108 also showed a \"favorable\" safety profile and support anti-fibrotic activity, expanding development potential into fibrostenotic Crohn's disease, Palisade said.The company said it expects to begin patient dosing in a phase 1b trial in fibrostenotic Crohn's disease within the year and targets to file in H1 of 2026 an investigational new drug application for a phase 2 trial.Palisade shares were up more than 4% in recent trading Wednesday.Price: 0.63, Change: +0.03, Percent Change: +4.58","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PALI":"Palisade Bio Inc.","BK4007":"制药","BK4139":"生物科技"},"translate_title":"Palisade Bio称溃疡性结肠炎患者在1b期试验中对PALI-2108治疗有反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PALI":1.5},"content_text":"Palisade Bio (PALI) said Wednesday that a phase 1b trial of its investigational drug PALI-2108 in ulcerative colitis showed 100% clinical response, with all five patients responding to treatment.The study also showed \"promising\" efficacy data, with two of the five patients achieving clinical remission after seven days based on US Food and Drug Administration-defined endpoints, the company said.PALI-2108 also showed a \"favorable\" safety profile and support anti-fibrotic activity, expanding development potential into fibrostenotic Crohn's disease, Palisade said.The company said it expects to begin patient dosing in a phase 1b trial in fibrostenotic Crohn's disease within the year and targets to file in H1 of 2026 an investigational new drug application for a phase 2 trial.Palisade shares were up more than 4% in recent trading Wednesday.Price: 0.63, Change: +0.03, Percent Change: +4.58","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}